• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVOCURE OPTUNE; STIMULATOR, LOW ELECTRIC FIELD, TUMOR TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVOCURE OPTUNE; STIMULATOR, LOW ELECTRIC FIELD, TUMOR TREATMENT Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Fatigue (1849); Twitching (2172); Shaking/Tremors (2515); No Code Available (3191)
Event Date 12/25/2016
Event Type  Injury  
Event Description
The reporter states that the patient began using the product on (b)(6) 2016 in order to treat his glioblastoma condition.The reporter states that on (b)(6), the patient began experiencing side effects such as extreme fatigue, muscle twitching, hand tremors, and increased difficulty of staying focused.The reporter states that the patient has discontinued use of the device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTUNE
Type of Device
STIMULATOR, LOW ELECTRIC FIELD, TUMOR TREATMENT
Manufacturer (Section D)
NOVOCURE
MDR Report Key6278905
MDR Text Key65914763
Report NumberMW5067447
Device Sequence Number1
Product Code NZK
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Caregivers
Type of Report Initial
Report Date 01/25/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received01/25/2017
Type of Device Usage N
Patient Sequence Number1
Treatment
DECADRON; KEPPRA; TEMOZOLOMIDE
Patient Outcome(s) Required Intervention;
Patient Age61 YR
Patient Weight75
-
-